Immune Complex Events in Connective Tissue Disease

1973 ◽  
Vol 45 (1-2) ◽  
pp. 183-184
Author(s):  
C.L. Christian
1978 ◽  
Vol 65 (5) ◽  
pp. 855-863 ◽  
Author(s):  
Michael B. Jones ◽  
Richard K. Osterholm ◽  
Richard B. Wilson ◽  
Franklin H. Martin ◽  
James R. Commers ◽  
...  

2005 ◽  
Vol 44 (10) ◽  
pp. 1112-1113 ◽  
Author(s):  
Masato MORIGUCHI ◽  
Keisuke NAKA ◽  
Tokutaro TSUDA ◽  
Hitoshi SUGAWARA ◽  
Hiroshi KAJIYAMA ◽  
...  

1977 ◽  
Vol 62 (5) ◽  
pp. 761-764 ◽  
Author(s):  
Thomas J. Fuller ◽  
Alan V. Richman ◽  
David Auerbach ◽  
Ronald W. Alexander ◽  
Richard Lottenberg ◽  
...  

Author(s):  
Lesley-Anne Bissell ◽  
Dwomoa Adu ◽  
Paul Emery

Renal disease is a well-recognized cause of ill health and death in rheumatoid arthritis. Three broad categories of renal disease occur. The first—and by far the most common—arises from the nephrotoxicity of the drugs used in the treatment of arthritis, particularly with non-steroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as gold and D-penicillamine may lead to proteinuria and a glomerulonephritis in 10–30% of patients. Ciclosporin is associated with significant nephrotoxicity and hypertension. A second major but diminishing cause of renal disease in rheumatoid arthritis is amyloidosis. Thirdly, rheumatoid arthritis may be associated with the development of glomerulonephritis. The main types described are a mesangial proliferative glomerulonephritis with or without immunoglobulin A deposits, a membranous nephropathy, and a focal segmental necrotizing glomerulonephritis of the vasculitic type.Renal disease in mixed connective tissue disease and polymyositis is infrequent, but the former can be associated with a membranous and mesangial proliferative glomerulonephritis.Sjögren syndrome is rarely associated with clinically significant renal disease, but patients can present with proteinuria, acidosis, or hyperchloraemia. Interstitial nephritis and immune complex glomerulonephritis reflect the exocrinopathy and circulating immune complex disease pathognomonic of Sjögren syndrome. Evidence for effective treatment of the renal complications is lacking. Corticosteroids and cyclophosphamide are most commonly used, with newer biological drugs, such as rituximab, showing promise.


Sign in / Sign up

Export Citation Format

Share Document